September 16, 2013

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.

The following patent record is from the CAplusSM database.


Patent Number: WO 20133095761
Title: Preparation of imidazopyridine derivatives as PI3 kinase inhibitors
Inventor(s): Rivero, Ralph A.; Tedesco, Rosanna
Patent Assignee(s): Glaxosmithkline LLC, USA
Source: PCT Int. Appl., 67pp. CODEN: PIXXD2
Language: English

This invention relates to the use of imidazopyridine derivs. I [R1 = H, OH, CO2H; R2 = H, alkyl; R6 and R7 = alkyl, halo, CF3; or R6 and R7 combine with the ring to which they are attached to form naphthyl] for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3'OH kinase family (hereinafter PI3 kinases), suitably, PI3Ka, PI3Kd, PI3Kß, and/or PI3K?.  Eight compds. I were prepd. and formulated.  E.g., a multi-step synthesis of II, starting from 1H-imidazo[4,5-b]pyridine, was described.  Exemplified compds. I were tested and found to be inhibitors of PI3 kinases, particularly PI3Kß. The activities (IC50) of exemplified compds. range from about 1 nM to about 10 µM against PI3Kß.  Suitably, the present invention relates to the use of imidazopyridines I in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.  More suitably, the present invention relates to PI3Kß selective imidazopyridine compds. for treating cancer.

Please note:  Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention.

 View the full-text here.

Recent News

    March 17, 2015 | New Content Provides Regulatory
    Professionals with Additional Value
    February 9, 2015 | Major New STN Release Delivers
    Essential Biomedical and Patent Content to IP
    January 26, 2015
 | Annual MEDLINE Reload on STN
    Features Enhanced Clinical Trial Information and the
    2015 MeSH Thesaurus
                                                                     More News >> 

 Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624